Discovery and Optimization of Potent and Orally Available CTP Synthetase Inhibitors for Use in Treatment of Diseases Driven by Aberrant Immune Cell Proliferation

Herein, we report the discovery of
a first-in-class chemotype 2-(alkylsulfonamido)­thiazol-4-yl)­acetamides
that act as pan-selective inhibitors of cytidine 5′-triphosphate
synthetase (CTPS1/2), critical enzymes in the de novo pyrimidine synthesis pathway. Weak inhibitors identified from a
high-throughput screening of 240K compounds have been optimized to
a potent, orally active agent, compound 27, which has
shown significant pharmacological responses at 10 mg/kg dose BID in
a well-established animal model of inflammation.